CN108752300B - 苄烯叉苯肽类化合物及其药物组合物和其应用 - Google Patents
苄烯叉苯肽类化合物及其药物组合物和其应用 Download PDFInfo
- Publication number
- CN108752300B CN108752300B CN201810469065.9A CN201810469065A CN108752300B CN 108752300 B CN108752300 B CN 108752300B CN 201810469065 A CN201810469065 A CN 201810469065A CN 108752300 B CN108752300 B CN 108752300B
- Authority
- CN
- China
- Prior art keywords
- compound
- benzylidene
- preparation
- phenylene
- peptide compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 63
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 24
- -1 Benzylidene phenylene Chemical group 0.000 title claims abstract description 20
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 10
- 238000002360 preparation method Methods 0.000 claims abstract description 25
- 208000018737 Parkinson disease Diseases 0.000 claims abstract description 20
- 239000003814 drug Substances 0.000 claims abstract description 11
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 48
- 238000006243 chemical reaction Methods 0.000 claims description 23
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 17
- 238000004440 column chromatography Methods 0.000 claims description 16
- 238000001914 filtration Methods 0.000 claims description 14
- 239000012074 organic phase Substances 0.000 claims description 13
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 10
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 10
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 claims description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- 229940127007 Compound 39 Drugs 0.000 claims description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 238000010791 quenching Methods 0.000 claims description 7
- 238000000926 separation method Methods 0.000 claims description 7
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 230000002829 reductive effect Effects 0.000 claims description 6
- 230000000171 quenching effect Effects 0.000 claims description 5
- 229940126639 Compound 33 Drugs 0.000 claims description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 claims description 4
- 230000003197 catalytic effect Effects 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- CJNZAXGUTKBIHP-UHFFFAOYSA-N 2-iodobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1I CJNZAXGUTKBIHP-UHFFFAOYSA-N 0.000 claims description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 3
- 229910021592 Copper(II) chloride Inorganic materials 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 229940086616 Monoamine oxidase B inhibitor Drugs 0.000 claims description 3
- 229910006124 SOCl2 Inorganic materials 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Substances ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims description 3
- 108010043958 Peptoids Proteins 0.000 claims description 2
- 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 102000010909 Monoamine Oxidase Human genes 0.000 abstract description 47
- 108010062431 Monoamine oxidase Proteins 0.000 abstract description 47
- 230000005764 inhibitory process Effects 0.000 abstract description 19
- 238000002474 experimental method Methods 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 7
- 239000003112 inhibitor Substances 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 4
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 238000000338 in vitro Methods 0.000 abstract description 2
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 42
- 238000005160 1H NMR spectroscopy Methods 0.000 description 21
- 239000000243 solution Substances 0.000 description 10
- 230000003291 dopaminomimetic effect Effects 0.000 description 6
- 235000019341 magnesium sulphate Nutrition 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- CYDRXTMLKJDRQH-UHFFFAOYSA-N benzododecinium Chemical class CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- BGAJNPLDJJBRHK-UHFFFAOYSA-N 3-[2-[5-(3-chloro-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-3-methyl-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl]propanoic acid Chemical compound C1=C(Cl)C(OC(C)C)=CC=C1C1=NN=C(N2C(=C3CN(CCC(O)=O)CCC3=N2)C)S1 BGAJNPLDJJBRHK-UHFFFAOYSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical class OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- RNXYXIKLWRRZNU-UHFFFAOYSA-N Kynuramine Natural products NCCCC(=O)C1=CC=CC=N1 RNXYXIKLWRRZNU-UHFFFAOYSA-N 0.000 description 2
- 206010029350 Neurotoxicity Diseases 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010044221 Toxic encephalopathy Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 229940082992 antihypertensives mao inhibitors Drugs 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 210000004227 basal ganglia Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 2
- JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical class CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- QLPVTIQQFGWSQQ-UHFFFAOYSA-N kynuramine Chemical compound NCCC(=O)C1=CC=CC=C1N QLPVTIQQFGWSQQ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 2
- 230000007135 neurotoxicity Effects 0.000 description 2
- 231100000228 neurotoxicity Toxicity 0.000 description 2
- 239000000668 oral spray Substances 0.000 description 2
- 229940041678 oral spray Drugs 0.000 description 2
- 238000007833 oxidative deamination reaction Methods 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 229960003424 phenylacetic acid Drugs 0.000 description 2
- 239000003279 phenylacetic acid Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- DZGWFCGJZKJUFP-UHFFFAOYSA-N tyramine Chemical compound NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 2
- GPVLEWBCVBRLJE-NVMNQCDNSA-N (1Z)-1-[(4-fluorophenyl)methylidene]benzo[f][2]benzofuran-3-one Chemical compound C1=CC=C2C=C3C(=CC2=C1)/C(=C/C4=CC=C(C=C4)F)/OC3=O GPVLEWBCVBRLJE-NVMNQCDNSA-N 0.000 description 1
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
- PPYOILMJGQANDM-BUHFOSPRSA-N (3E)-3-[chloro-(4-chlorophenyl)methylidene]-2-benzofuran-1-one Chemical compound C1=CC=C2C(=C1)/C(=C(/C3=CC=C(C=C3)Cl)\Cl)/OC2=O PPYOILMJGQANDM-BUHFOSPRSA-N 0.000 description 1
- OODPDLZFVDTOBT-ZSOIEALJSA-N (3Z)-3-[(3,4-difluorophenyl)methylidene]-2-benzofuran-1-one Chemical compound C1=CC=C2C(=C1)/C(=C/C3=CC(=C(C=C3)F)F)/OC2=O OODPDLZFVDTOBT-ZSOIEALJSA-N 0.000 description 1
- TWFDIKOXKSCOGG-ZROIWOOFSA-N (3Z)-3-[(3-chlorophenyl)methylidene]-2-benzofuran-1-one Chemical compound ClC1=CC=CC(\C=C/2C3=CC=CC=C3C(=O)O\2)=C1 TWFDIKOXKSCOGG-ZROIWOOFSA-N 0.000 description 1
- FBKMQDOXTNAILY-RGEXLXHISA-N (3Z)-3-[(4-pentylphenyl)methylidene]-2-benzofuran-1-one Chemical compound CCCCCC1=CC=C(C=C1)/C=C\2/C3=CC=CC=C3C(=O)O2 FBKMQDOXTNAILY-RGEXLXHISA-N 0.000 description 1
- TXUFWNVVIADQAO-ATVHPVEESA-N (3Z)-3-[(4-tert-butylphenyl)methylidene]-2-benzofuran-1-one Chemical compound CC(C)(C)c1ccc(\C=C2/OC(=O)c3ccccc23)cc1 TXUFWNVVIADQAO-ATVHPVEESA-N 0.000 description 1
- XOXXHMJVXJQBAU-QPEQYQDCSA-N (3Z)-3-[(5-bromopyridin-2-yl)methylidene]-2-benzofuran-1-one Chemical compound C1=CC=C2C(=C1)/C(=C/C3=NC=C(C=C3)Br)/OC2=O XOXXHMJVXJQBAU-QPEQYQDCSA-N 0.000 description 1
- SCVIKHYOEUHXMY-ZROIWOOFSA-N (3Z)-3-[[4-(trifluoromethyl)phenyl]methylidene]-2-benzofuran-1-one Chemical compound C1=CC(C(F)(F)F)=CC=C1\C=C/1C2=CC=CC=C2C(=O)O\1 SCVIKHYOEUHXMY-ZROIWOOFSA-N 0.000 description 1
- HXFCYKXSUURMAX-AUWJEWJLSA-N (3Z)-6-chloro-3-[(4-fluorophenyl)methylidene]-2-benzofuran-1-one Chemical compound C1=CC(=CC=C1/C=C\2/C3=C(C=C(C=C3)Cl)C(=O)O2)F HXFCYKXSUURMAX-AUWJEWJLSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- SXVPWSRPVGNBJE-PDGQHHTCSA-N (3z)-3-(naphthalen-2-ylmethylidene)-2-benzofuran-1-one Chemical compound C12=CC=CC=C2C(=O)O\C1=C/C1=CC=C(C=CC=C2)C2=C1 SXVPWSRPVGNBJE-PDGQHHTCSA-N 0.000 description 1
- HQTZOLYGVQALEU-ZSOIEALJSA-N (3z)-3-[(3,4-dichlorophenyl)methylidene]-2-benzofuran-1-one Chemical compound C1=C(Cl)C(Cl)=CC=C1\C=C/1C2=CC=CC=C2C(=O)O\1 HQTZOLYGVQALEU-ZSOIEALJSA-N 0.000 description 1
- DYCNZHKCQPNJML-GDNBJRDFSA-N (3z)-3-[(3-methylphenyl)methylidene]-2-benzofuran-1-one Chemical compound CC1=CC=CC(\C=C/2C3=CC=CC=C3C(=O)O\2)=C1 DYCNZHKCQPNJML-GDNBJRDFSA-N 0.000 description 1
- GBOCONZWDUTOQA-ZROIWOOFSA-N (3z)-3-[(4-bromophenyl)methylidene]-2-benzofuran-1-one Chemical compound C1=CC(Br)=CC=C1\C=C/1C2=CC=CC=C2C(=O)O\1 GBOCONZWDUTOQA-ZROIWOOFSA-N 0.000 description 1
- OHRFHJYUEWVXBD-ZROIWOOFSA-N (3z)-3-[(4-chlorophenyl)methylidene]-2-benzofuran-1-one Chemical compound C1=CC(Cl)=CC=C1\C=C/1C2=CC=CC=C2C(=O)O\1 OHRFHJYUEWVXBD-ZROIWOOFSA-N 0.000 description 1
- YUUDPCAZITYZNH-ZROIWOOFSA-N (3z)-3-[(4-fluorophenyl)methylidene]-2-benzofuran-1-one Chemical compound C1=CC(F)=CC=C1\C=C/1C2=CC=CC=C2C(=O)O\1 YUUDPCAZITYZNH-ZROIWOOFSA-N 0.000 description 1
- XBPLURLJIACOAL-GDNBJRDFSA-N (3z)-3-[(4-methoxyphenyl)methylidene]-2-benzofuran-1-one Chemical compound C1=CC(OC)=CC=C1\C=C/1C2=CC=CC=C2C(=O)O\1 XBPLURLJIACOAL-GDNBJRDFSA-N 0.000 description 1
- HYLSWFOHDJRUGQ-GDNBJRDFSA-N (3z)-3-[(4-methylphenyl)methylidene]-2-benzofuran-1-one Chemical compound C1=CC(C)=CC=C1\C=C/1C2=CC=CC=C2C(=O)O\1 HYLSWFOHDJRUGQ-GDNBJRDFSA-N 0.000 description 1
- UICVKJHQZUAKLT-ZROIWOOFSA-N (3z)-3-[(4-nitrophenyl)methylidene]-2-benzofuran-1-one Chemical compound C1=CC([N+](=O)[O-])=CC=C1\C=C/1C2=CC=CC=C2C(=O)O\1 UICVKJHQZUAKLT-ZROIWOOFSA-N 0.000 description 1
- ICCBGFWJTALFFU-UVTDQMKNSA-N (3z)-3-benzylideneisoindol-1-one Chemical compound C12=CC=CC=C2C(=O)N\C1=C/C1=CC=CC=C1 ICCBGFWJTALFFU-UVTDQMKNSA-N 0.000 description 1
- KKHFRAFPESRGGD-UHFFFAOYSA-N 1,3-dimethyl-7-[3-(n-methylanilino)propyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCCN(C)C1=CC=CC=C1 KKHFRAFPESRGGD-UHFFFAOYSA-N 0.000 description 1
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 1
- ROBMZRGIEDJEMQ-UHFFFAOYSA-N 3-[(4-fluorophenyl)methyl]-3H-2-benzofuran-1-one Chemical compound C1=CC=C2C(=C1)C(OC2=O)CC3=CC=C(C=C3)F ROBMZRGIEDJEMQ-UHFFFAOYSA-N 0.000 description 1
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 1
- HCCNBKFJYUWLEX-UHFFFAOYSA-N 7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)-3-(pyrazin-2-ylmethylamino)pyrido[3,4-b]pyrazin-2-one Chemical compound O=C1N(CCOCCC)C2=CC(C=3C=NC(OC)=CC=3)=NC=C2N=C1NCC1=CN=CC=N1 HCCNBKFJYUWLEX-UHFFFAOYSA-N 0.000 description 1
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 1
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 1
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
- XJNLGILMYISDGH-GDNBJRDFSA-N COC1=CC=CC(\C=C/2C3=CC=CC=C3C(=O)O\2)=C1 Chemical compound COC1=CC=CC(\C=C/2C3=CC=CC=C3C(=O)O\2)=C1 XJNLGILMYISDGH-GDNBJRDFSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229960001716 benzalkonium Drugs 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229940125878 compound 36 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 229940127271 compound 49 Drugs 0.000 description 1
- 229940126545 compound 53 Drugs 0.000 description 1
- 229940127113 compound 57 Drugs 0.000 description 1
- 229940125900 compound 59 Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- ZTCZYTZOLQUGOY-UHFFFAOYSA-N cyclohexa-2,4-dien-1-ylidenemethylbenzene Chemical compound C1C=CC=CC1=CC1=CC=CC=C1 ZTCZYTZOLQUGOY-UHFFFAOYSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- PMZDQRJGMBOQBF-UHFFFAOYSA-N quinolin-4-ol Chemical compound C1=CC=C2C(O)=CC=NC2=C1 PMZDQRJGMBOQBF-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229960003732 tyramine Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
- C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/92—Naphthofurans; Hydrogenated naphthofurans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明提供苄烯叉苯肽类化合物,以其为活性成分的药物组合物,及其作为单胺氧化酶B(MAO‑B)抑制剂,和在制备帕金森症(PD)治疗药物中的应用。单胺氧化酶B(MAO‑B)已被证实与帕金森症(PD)病因存在着密切联系,是该病药物研发的经典靶标。本发明提供了苄烯叉苯肽类化合物在制备单胺氧化酶B(MAO‑B)抑制剂中的应用。该系列化合物经过体外激酶活性实验,证明其有明显的单胺氧化酶B(MAO‑B)抑制作用。
Description
技术领域
本发明涉及医药技术领域,具体涉及苄烯叉苯肽类化合物,以它们为活性成分的药物组合物,以及它们在制备单胺氧化酶B(Monoamine Oxidase B,MAO-B)抑制剂中的应用,和它们在制备治疗帕金森症(Parkinson’s Disease,PD)的药物中的应用。
背景技术
帕金森病(Parkinson’s disease,PD)是一种常见的神经系统退行性性疾病,平均发病年龄为60岁左右,严重危及老年人的健康,对社会和经济造成巨大的影响。帕金森病最主要的病理改变是基底神经节黑质多巴胺(dopamine,DA)能神经元的变性死亡,由此而引起纹状体DA含量显著性减少而致病。
单胺氧化酶(Monoamine Oxidase,MAO)是人体内催化单胺类物质氧化脱氨反应的酶,其氧化脱氨的产物为相应的醛、胺以及过氧化氢。根据底物的不同,单胺氧化酶分为MAO-A和MAO-B两种。MAO-B在脑组织的基底神经节部位有大量分布,并且活性随年龄增长而增加。由于MAO-B可以代谢DA,加重了PD患者脑部相关部位的DA缺失。另外,由于MAO-B催化反应产生的醛和过氧化氢均有神经细胞毒性,而PD患者黑质部位醛脱氢酶不足强化了由MAO-B催化反应导致的神经毒性。因此抑制MAO-B可以通过升高脑中DA等单氨神经递质和降低神经毒性两种途径治疗PD。
早期桎梏MAO抑制剂应用的主要原因在于患者使用不可逆和非选择性MAO抑制剂时需要严格遵守低酪饮食方针,防止由于摄入酪胺触发致命性高血压。但是随着研究深入发现MAO-B在人体内比例和分布特点,现在一般均认为可逆和选择性MAO-B抑制剂在PD治疗是安全和可接受的。因此本发明的目的是提供符合上述标准的、具有不同于以往的新型结构骨架的化合物。本发明的式(I)化合物具有成为选择性MAO-B抑制剂的潜力,至今未见该化合物在治疗PD的相关报道。
发明内容
本发明的目的是提供苄烯叉苯肽类化合物,开发具有同类骨架的先导化合物。提供苄烯叉苯肽类化合物在制备治疗帕金森症的药物中的应用,可作为治疗帕金森症的药物,而且本发明化合物易合成,成本廉价和副作用小。
为了实现本发明的上述目的,本发明提供了如下的技术方案:
如下结构式(I)所示的苄烯叉苯肽类衍生物,
式(I)中,X为如下基团之一:
Y为如下基团之一:
R1、R2、R3、R4、R5、R6、R7、R8、R9相互独立的选自:
-H、-CH3、-CH2CH3、-CH2CH2CH3、-CH(CH3)2、-C(CH3)3、-CH2CH2CH2CH2CH3、-CH2OH、-OH、-OCH3、-OCH2CH3、-CF3、-CN、-F、-Cl、-Br、-I、-NO2、-N(CH3)2、-NH2、-NHAc、
如下结构式所示的苄烯叉苯肽化合物32、33、35、36、37、40、42、47、48、49、50、51、53、56、57、58、59、62、44、43、39,
药物组合物,其包含所述的苄烯叉苯肽类化合物和至少一种药学上可接受的载体。
所述的苄烯叉苯肽类化合物在制备单胺氧化酶B抑制剂的应用。
所述的苄烯叉苯肽类化合物用作为单胺氧化酶B抑制剂。
所述的苄烯叉苯肽类化合物在制备治疗帕金森症的药物中的应用。
所述的苄烯叉苯肽类化合物的制备方法,其化学反应方程式如下:
将相应取代邻苯二甲酸酐1mmol、相应取代苯乙酸1mmol和碱0.1mmol加入密封管,100-200℃加热,反应完成后,冷至室温,加入50ml二氯甲烷溶解,用饱和食盐水洗涤,收集有机相柱层析分离,即可得到相应苯肽化合物32、33、35、36、37、40、42、47、48、49、50、51、53、56、57、58、59、62,
苄烯叉苯肽类化合物44的制备方法,其化学反应方程式如下:
将化合物33溶于甲醇,加入10%重量比Pd/C,在室温下用氢气还原,反应完成后,过滤除去Pd/C,柱层析分离化合物44。
苄烯叉苯肽类化合物43的制备方法,其化学反应方程式如下:
将化合物SPECS-115、CuI、Cs2CO3、NH4OAc在氩气保护下下反应,反应结束后,加水淬灭,用二氯甲烷萃取,饱和食盐水洗涤,合并有机相,无水MgSO4干燥,过滤浓缩后柱层析分离得到化合物43。
苄烯叉苯肽类化合物39的制备方法,其化学反应方程式如下:
中间体A的制备:邻碘苯甲酸、SOCl2和催化量的DMF在DCM中室温反应4h后,减压蒸馏除去溶剂,在冰盐浴下加入DCM、N,O-二甲羟胺盐酸盐和吡啶,随后转移至室温反应至转化完毕,用二氯甲烷和饱和食盐水萃取,合并有机相用无水MgSO4干燥,过滤浓缩柱层析分离得到中间体A;
中间体B的制备:中间体A、Pd(PPh3)4、对氯苯乙炔和n-BuNH2溶于THF,于室温下至反应结束,加入饱和氯化铵溶液淬灭,二氯甲烷萃取,合并有机相后用MgSO4干燥,过滤浓缩后柱层析分离得到中间体B;
化合物39的制备:中间体B、CuCl2和NCS溶于乙腈,加热反应至结束,加水淬灭,二氯甲烷萃取,合并有机相用无水MgSO4干燥,过滤浓缩后柱层析分离得到化合物39。
本发明通过长期研究首次发现并通过活性测试,验证了本发明式(I)的苄烯叉苯肽类化合物具有单氨氧化酶B(MAO-B)抑制活性。该类化合物结构新颖,化学上易于合成。同时本发明还提供了式(I)中苄烯叉苯肽类化合物作为单氨氧化酶B(MAO-B)靶标抑制剂的新用途。
本发明化合物用作药物时,可以直接使用,或者以药物组合物的形式使用。该药物组合物含有0.1–99%,优选为0.5–90%的本发明化合物,其余为药物学上可接受的,对人和动物无毒和惰性的可药用载体或赋形剂。
所述的可药用载体或赋形剂是一种或多种选自固体、半固体和液体稀释剂、超填料以及药物制品辅剂。将所述的有效提取物或有效部位以单位体重服用量的形式使用。本发明的药物可经口服和口腔喷雾两种形式给药。
口服可用其固体或液体制剂,如粉剂、片剂、糖衣片剂、胶囊、酊剂、糖浆、滴丸剂等。
口腔喷雾可用其固体或液体制剂。
本发明药物可用于治疗帕金森症。
附图说明
附图1和附图2为本发明苄烯叉苯肽类化合物SPECS-87和SPECS-115对单氨氧化酶B(MAO-B)的体外抑制曲线图。
具体实施方式
下面结合附图,用本发明的下述实施例对本发明的实质性内容进行详细叙述,但并不以此来限定本发明。
实施例1:
本发明化合物部分购自荷兰specs公司(网址:http://www.specs.com),这一部分的化合物在库中相应的编号如下:
化合物 | 编号 | 化合物 | 编号 |
SPECS-87 | AJ-030/12105309 | SPECS-115 | AE-641/05032029 |
实施例2:
将相应取代邻苯二甲酸酐(1mmol)、相应取代苯乙酸(1mmol)和碱(0.1mmol)加入密封管,100-200℃加热。反应完成后,冷至室温,加入50ml二氯甲烷溶解,用饱和食盐水洗涤,收集有机相柱层析分离,即可得到相应苯肽化合物。该方法适用于实施例3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20。
实施例3:
化合物32
(Z)-3-(4-methoxybenzylidene)isobenzofuran-1(3H)-one
1H NMR(400MHz,CDCl3)δ7.93(d,J=7.6Hz,1H),7.82(d,J=8.8Hz,2H),7.72(m,2H),7.52(t,J=7.2Hz,1H),6.95(d,J=8.8Hz,2H),6.39(s,1H),3.86(s,3H).
实施例4:
化合物33
(Z)-3-(4-fluorobenzylidene)isobenzofuran-1(3H)-one
1H NMR(400MHz,CDCl3)δ7.95(d,J=8.0Hz,1H),7.84(dd,J=8.4,5.6Hz,2H),7.77–7.71(m,2H),7.56(t,J=7.1Hz,1H),7.10(t,J=8.4Hz,2H),6.39(s,1H).
实施例5:
化合物35
(Z)-3-(4-chlorobenzylidene)isobenzofuran-1(3H)-one
1H NMR(400MHz,CDCl3)δ7.95(d,J=7.6Hz,1H),7.84–7.67(m,3H),7.61–7.52(m,1H),7.38(d,J=8.4Hz,2H),6.38(s,1H).
实施例6:
化合物36
(Z)-3-(3-chlorobenzylidene)isobenzofuran-1(3H)-one
1H NMR(400MHz,CDCl3)δ7.96(d,J=7.6Hz,1H),7.83(s,1H),7.77–7.73(m,2H),7.63–7.56(m,1H),7.35(t,J=8.0Hz,1H),7.29(d,J=8.4Hz,1H),7.20–7.09(m,1H),6.36(s,1H).
实施例7:
化合物37
(Z)-3-(4-methylbenzylidene)isobenzofuran-1(3H)-one
1H NMR(400MHz,CDCl3)δ7.94(d,J=7.6Hz,1H),7.81–7.66(m,3H),7.54(t,J=7.6Hz,1H),7.23(d,J=8.0Hz,2H),6.41(s,1H),2.39(s,3H).
实施例8:
化合物40
(Z)-3-(3-methoxybenzylidene)isobenzofuran-1(3H)-one
1H NMR(400MHz,CDCl3)δ7.95(d,J=7.6Hz,1H),7.82–7.68(m,2H),7.55(t,J=7.2Hz,1H),7.43(dd,J=3.6,1.6Hz,2H),7.32(dd,J=12.0,8.0Hz,1H),6.89(dd,J=8.4,2.0Hz,1H),6.40(s,1H),3.88(s,3H).
实施例9:
化合物42
(Z)-3-(4-bromobenzylidene)isobenzofuran-1(3H)-one
1H NMR(400MHz,CDCl3)δ7.95(d,J=7.6Hz,1H),7.81–7.68(m,4H),7.62–7.49(m,3H),6.36(s,1H).
实施例10:
化合物47
(Z)-3-(4-nitrobenzylidene)isobenzofuran-1(3H)-one
1H NMR(400MHz,CDCl3)δ8.27(d,J=8.8Hz,1H),8.00(d,J=8.8Hz,1H),7.81(dt,J=12.8,7.6Hz,1H),7.64(t,J=6.8Hz,1H),6.47(s,1H).
实施例11:
化合物48
(Z)-3-(3,4-dichlorobenzylidene)isobenzofuran-1(3H)-one
1H NMR(400MHz,CDCl3)δ7.97(d,J=7.6Hz,1H),7.92(d,J=2.0Hz,1H),7.79–7.73(m,2H),7.71(dd,J=8.4,2.0Hz,1H),7.60(ddd,J=8.8,6.0,2.2Hz,1H),7.48(d,J=8.8Hz,1H),6.32(s,1H).
实施例12:
化合物49
(Z)-3-(3,4-difluorobenzylidene)isobenzofuran-1(3H)-one
1H NMR(400MHz,CDCl3)δ7.95(d,J=7.6Hz,1H),7.81–7.70(m,3H),7.62–7.55(m,1H),7.54–7.46(m,1H),7.19(dd,J=18.4,8.4Hz,1H),6.33(s,1H).
实施例13:
化合物50
(Z)-3-((5-bromopyridin-2-yl)methylene)isobenzofuran-1(3H)-one
1H NMR(400MHz,CDCl3)δ7.96(d,J=7.76Hz,1H),7.82–7.68(m,3H),7.62–7.56(m,1H),7.56–7.48(m,1H),7.19(dd,J=18.4,8.4Hz,1H),6.33(s,1H).
实施例14:
化合物51
(Z)-6-chloro-3-(4-fluorobenzylidene)isobenzofuran-1(3H)-one
1H NMR(400MHz,CDCl3)δ7.91(s,1H),7.87–7.79(m,2H),7.70(s,2H),7.11(t,J=8.8Hz,2H),6.38(s,1H).
实施例15:
化合物53
(Z)-3-(4-(trifluoromethyl)benzylidene)isobenzofuran-1(3H)-one
1H NMR(400MHz,CDCl3)δ7.97(t,J=8.8Hz,2H),7.81(t,J=8.0Hz,1H),7.76(d,J=7.6Hz,1H),7.66(d,J=8.4Hz,2H),7.61(t,J=7.2Hz,1H),6.45(s,1H).
实施例16:
化合物56
(Z)-3-(naphthalen-2-ylmethylene)isobenzofuran-1(3H)-one
1H NMR(400MHz,CDCl3)δ8.26(s,1H),8.04(d,J=1.2Hz,1H),7.97(d,J=7.6Hz,1H),7.91-7.88(m,2H),7.86-7.81(m,2H),7.75(t,J=7.3Hz,1H),7.57(t,J=7.4Hz,1H),7.53–7.44(m,2H),6.60(s,1H).
实施例17:
化合物57
(Z)-3-(4-fluorobenzylidene)naphtho[2,3-c]furan-1(3H)-one
1H NMR(400MHz,CDCl3)δ8.51(d,J=4.0Hz,1H),8.20(s,1H),8.02(dd,J=18.0,8.0Hz,2H),7.86(t,J=6.0Hz,2H),7.68(t,J=7.2Hz,1H),7.61(t,J=7.6Hz,1H),7.11(t,J=8.4Hz,2H),6.52(d,J=3.2Hz,1H).
实施例18:
化合物58
(Z)-3-(4-(tert-butyl)benzylidene)isobenzofuran-1(3H)-one
1H NMR(400MHz,CDCl3)δ7.94(d,J=7.6Hz,1H),7.84–7.75(m,3H),7.72(t,J=7.2Hz,1H),7.53(d,J=7.2Hz,1H),7.44(d,J=8.4Hz,2H),6.43(s,1H),1.35(s,9H).
实施例19:
化合物59
(Z)-3-(4-pentylbenzylidene)isobenzofuran-1(3H)-one
1H NMR(400MHz,CDCl3)δ7.96(t,J=7.2Hz,1H),7.77(d,J=8.0Hz,1H),7.72(t,J=7.4Hz,1H),7.54(t,J=7.6Hz,1H),7.23(d,J=8.0Hz,1H),6.42(s,1H),2.73–2.50(m,2H),1.65(dd,J=14.8,7.2Hz,2H),1.34(d,J=3.2Hz,5H),0.90(t,J=7.2Hz,3H).
实施例20:
化合物62
(Z)-3-(3-methylbenzylidene)isobenzofuran-1(3H)-one
1H NMR(400MHz,CDCl3)δ8.08(d,J=7.6Hz,1H),7.76(s,1H),7.67–7.62(m,2H),7.54(t,J=7.6Hz,1H),7.23(d,J=8.0Hz,2H),6.23(s,1H),2.43(s,3H).
实施例21:
将化合物33溶于甲醇,加入10wt%的Pd/C,在室温下用氢气还原,反应完成后,过滤除去Pd/C,柱层析分离化合物44。
化合物44
3-(4-fluorobenzyl)isobenzofuran-1(3H)-one
1H NMR(400MHz,CDCl3)δ7.84(d,J=7.6Hz,1H),7.63(t,J=7.2Hz,1H),7.50(t,J=7.6Hz,1H),7.24(d,J=4.4Hz,1H),7.16(dd,J=8.4,5.6Hz,2H),6.96(t,J=8.6Hz,2H),3.21(d,J=6.4Hz,1H).
实施例22:
将按照实施例1得到的化合物SPECS-115、CuI、Cs2CO3、NH4OAc在氩气保护下反应,反应结束后,加水淬灭,用二氯甲烷萃取,饱和食盐水洗涤,合并有机相,无水MgSO4干燥,过滤浓缩后柱层析分离得到化合物43。
化合物43
(Z)-3-benzylideneisoindolin-1-one
1H NMR(400MHz,CDCl3)δ8.13(bs,1H),7.88(d,J=7.2Hz,1H),7.80(d,J=8.0Hz,1H),7.68–7.62(m,1H),7.53(t,J=7.6Hz,1H),7.45(d,J=4.8Hz,4H),7.36–7.28(m,1H),6.56(s,1H).
实施例23:
中间体A的制备:邻碘苯甲酸、SOCl2和催化量的DMF在DCM中室温反应4h后,减压蒸馏除去溶剂,在冰盐浴下加入DCM、N,O-二甲羟胺盐酸盐和吡啶,随后转移至室温反应至转化完毕,用二氯甲烷和饱和食盐水萃取,合并有机相用无水MgSO4干燥,过滤浓缩柱层析分离得到中间体A。
中间体B的制备:中间体A、Pd(PPh3)4、对氯苯乙炔和n-BuNH2溶于THF,于室温下至反应结束,加入饱和氯化铵溶液淬灭,二氯甲烷萃取,合并有机相后用MgSO4干燥,过滤浓缩后柱层析分离得到中间体B。
化合物39的制备:中间体B、CuCl2和NCS溶于乙腈,加热反应至结束,加水淬灭,二氯甲烷萃取,合并有机相用无水MgSO4干燥,过滤浓缩后柱层析分离得到化合物39。
化合物39
(E)-3-(chloro(4-chlorophenyl)methylene)isobenzofuran-1(3H)-one
1H NMR(400MHz,CDCl3)δ8.49(d,J=8.0Hz,1H),8.00(d,J=7.6Hz,1H),7.81(dd,J=15.6,8.4Hz,1H),7.65(t,J=7.6Hz,1H),7.43(d,J=8.8Hz,1H).
实施例24:
本发明化合物在500nM浓度对对单胺氧化酶B(MAO-B)的抑制作用:
1、实验原理
单胺氧化酶B能够催化其底物类似物犬尿胺降解,生成4-喹啉醇。可以通过320nM激发波长/400nM发射波长检测反应生成的4-喹啉醇。化合物与单胺氧化酶B的混合液在37℃反应,如果化合物对单胺氧化酶B有抑制作用,那么单胺氧化酶B催化底物类似物犬尿胺降解的量就会减少,相应的反应产物4-喹啉醇减少,即在320nM激发波长/400nM发射波长的信号值变小,以此来筛选具有抑制活性的化合物。
2、实验操作过程
1)准备缓冲溶液;
2)准备2x的化合物溶液,取50μL到96孔板每孔中。最终DMSO浓度位2%;
3)准备4x的酶溶液;
4)准备4x底物溶液;
5)转移25μL的酶溶液到96孔板每孔中;在空白对照空中加入25μL的缓冲溶液;
6)在室温孵育15分钟;
7)加入25μL的底物溶液到96孔板每孔中启动酶反应;
8)在37℃反应30分钟;
9)加入20μL的2M NaOH溶液终止反应。
10)在320nM激发波长/400nM发射波长读取数据。
3、数据处理:
在Excel中按如下公式计算得到化合物对单胺氧化酶B的抑制率。
公式(1):
抑制率%=(最大值-实验值)/(最大值-空白值)*100
4、实验结果
表1化合物对单胺氧化酶B的抑制率
化合物 | 抑制率% | 化合物 | 抑制率% | 化合物 | 抑制率% |
56 | 97 | 57 | 93 | 58 | 98 |
59 | 67 | 62 | 87 | SPECS-87 | 94 |
SPECS-1115 | 84 |
实施例25:
本发明化合物在1.00μM浓度对对单胺氧化酶B(MAO-B)的抑制作用:
1、实验原理(同实施例24)。
2、实验操作过程(同实施例24)。
3、数据处理(同实施例24)。:
4、实验结果
表1化合物对单胺氧化酶B的抑制率
实施例26:
本发明化合物对单胺氧化酶B(MAO-B)抑制活性IC50的测定:
1、实验原理(同实施例24)。
2、实验操作过程(同实施例24)。
3、数据处理:
在Excel中按如下公式(1)计算得到化合物对单胺氧化酶B的抑制率。公式(1):
抑制率%=(最大值-实验值)/(最大值-空白值)*100
在GraphPad Prism 5按如下公式(2)计算得到化合物对单胺氧化酶B抑制的IC50值。
公式(2):
Y=Bottom+(Top-Bottom)/(1+10^((LogIC50-X)*Hill Slope))
Y是抑制率,X是化合物浓度。
4、实验结果
表3化合物对单胺氧化酶B抑制的IC50值
化合物 | IC<sub>50</sub>μM | 化合物 | IC<sub>50</sub>μM | 化合物 | IC<sub>50</sub>μM |
33 | 0.015 | 36 | 0.048 | 47 | 0.015 |
48 | 0.024 | 51 | 0.038 | 57 | 0.026 |
SPECS-87 | 0.057 | SPECS-115 | 0.086 |
实施例27∶
本发明化合物对单胺氧化酶A(MAO-A)抑制活性IC50的测定:
1、实验原理(同实施例24)。
2、实验操作过程(同实施例24)。
3、数据处理(同实施例26)。:
4、实验结果
表3化合物对单胺氧化酶A(MAO-A)抑制活性IC50
实施例28:
按实施例2-23制得本发明化合物,按其与赋形剂重量比1∶1的比例加入赋形剂,制粒压片。
实施例29:
按实施例2-23制得本发明化合物,按其与赋形剂重量比1:2的比例加入赋形剂,制粒压片。
实施例30:
按实施例2-23制得本发明化合物,按常规胶囊制剂方法制成胶囊。
实施例31:
按实施例2-23制得本发明化合物,再按下述方法制成片剂:
实施例32:
胶囊剂:本发明化合物 100mg
淀粉 适量
硬脂酸镁 适量
制备方法:将化合物与助剂混合,过筛,在合适的容器中均匀混合,把得到的混合物装入硬明胶胶囊。
实施例33:
制备方法:搅拌下于适当体积的重蒸馏水中每次加入一种成分,直至完全深解,然后再加入另一种成分。加水至2ml后,将该溶液在无菌过滤器上过滤,装入瓶中并按照适当的剂量分隔。
实施例34:
滴丸:本发明化合物 1g
聚乙二醇6000 9g
制法:化合物与聚乙二醇6000熔融液的制备:按上述处方量称取本发明化合物,加入适量无水乙醇,微热溶解后,加入处方量的聚乙二醇熔融液中(60℃水浴保温),搅拌混合均匀,直至乙醇挥尽为止,静置于60℃水浴中保温30分钟,待气泡除尽,然后将除尽气泡的上述混匀熔融液转入贮液筒内,在保温80-85℃的条件下,控制滴速,一滴滴地滴入冷凝液中,等冷凝完全,倾去冷凝液,收集滴丸,沥净和用滤纸除去丸上的冷凝液,放置硅胶干燥器中或自然干燥即可。
Claims (6)
2.药物组合物,其包含权利要求1所示的苄烯叉苯肽类化合物和至少一种药学上可接受的载体。
6.苄烯叉苯肽类化合物39的制备方法,其化学反应方程式如下:
中间体A的制备:邻碘苯甲酸、SOCl2和催化量的DMF在DCM中室温反应4h后,减压蒸馏除去溶剂,在冰盐浴下加入DCM、N,O-二甲羟胺盐酸盐和吡啶,随后转移至室温反应至转化完毕,用二氯甲烷和饱和食盐水萃取,合并有机相用无水MgSO4干燥,过滤浓缩柱层析分离得到中间体A;
中间体B的制备:中间体A、Pd(PPh3)4、对氯苯乙炔和n-BuNH2溶于THF,于室温下至反应结束,加入饱和氯化铵溶液淬灭,二氯甲烷萃取,合并有机相后用MgSO4干燥,过滤浓缩后柱层析分离得到中间体B;
化合物39的制备:中间体B、CuCl2和NCS溶于乙腈,加热反应至结束,加水淬灭,二氯甲烷萃取,合并有机相用无水MgSO4干燥,过滤浓缩后柱层析分离得到化合物39。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810469065.9A CN108752300B (zh) | 2018-05-16 | 2018-05-16 | 苄烯叉苯肽类化合物及其药物组合物和其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810469065.9A CN108752300B (zh) | 2018-05-16 | 2018-05-16 | 苄烯叉苯肽类化合物及其药物组合物和其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108752300A CN108752300A (zh) | 2018-11-06 |
CN108752300B true CN108752300B (zh) | 2022-03-25 |
Family
ID=64007902
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810469065.9A Active CN108752300B (zh) | 2018-05-16 | 2018-05-16 | 苄烯叉苯肽类化合物及其药物组合物和其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108752300B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111018818B (zh) * | 2019-12-16 | 2022-11-29 | 云南民族大学 | 一种手性苯酞类化合物及其氘代化合物的合成方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1105360A (zh) * | 1993-11-02 | 1995-07-19 | 杜菲尔国际开发有限公司 | 1-[2h-1-苯并吡喃-2-酮-8-基]-哌嗪衍生物 |
CN1330069A (zh) * | 2000-06-28 | 2002-01-09 | 中国医学科学院药物研究所 | 新的取代的2-苯并[c]呋喃酮化合物,其制备方法以及包含它们的药物组合物 |
WO2005087726A1 (de) * | 2004-03-12 | 2005-09-22 | Boehringer Ingelheim International Gmbh | Neue aryl-haltige 5-acylindolinone, deren herstellung und deren verwendung als arzneimittel |
CN102125548A (zh) * | 2010-01-13 | 2011-07-20 | 石药集团恩必普药业有限公司 | 丁苯酞及其衍生物在制备治疗帕金森病的药物中的应用 |
CN104042606A (zh) * | 2013-03-12 | 2014-09-17 | 国钦生物科技股份有限公司 | 苯酞化合物的应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6660736B2 (en) * | 2002-03-27 | 2003-12-09 | Hoffmann-La Roche Inc. | Phthalimido derivatives and a process for their preparation |
-
2018
- 2018-05-16 CN CN201810469065.9A patent/CN108752300B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1105360A (zh) * | 1993-11-02 | 1995-07-19 | 杜菲尔国际开发有限公司 | 1-[2h-1-苯并吡喃-2-酮-8-基]-哌嗪衍生物 |
CN1330069A (zh) * | 2000-06-28 | 2002-01-09 | 中国医学科学院药物研究所 | 新的取代的2-苯并[c]呋喃酮化合物,其制备方法以及包含它们的药物组合物 |
WO2005087726A1 (de) * | 2004-03-12 | 2005-09-22 | Boehringer Ingelheim International Gmbh | Neue aryl-haltige 5-acylindolinone, deren herstellung und deren verwendung als arzneimittel |
CN102125548A (zh) * | 2010-01-13 | 2011-07-20 | 石药集团恩必普药业有限公司 | 丁苯酞及其衍生物在制备治疗帕金森病的药物中的应用 |
CN104042606A (zh) * | 2013-03-12 | 2014-09-17 | 国钦生物科技股份有限公司 | 苯酞化合物的应用 |
Non-Patent Citations (7)
Title |
---|
Copper-Catalyzed Selective Synthesis of Isoindolin-1-ones and Isoquinolin-1-ones from the Three-Component Coupling of 2-Halobenzoic Acid, Alkynylcarboxylic Acid and Ammonium Acetate;Francis Mariaraj Irudayanathan 等;《Advanced Synthesis & Catalysis》;20140903;第356卷;参见第3437页路线6 * |
Improvement of antibacterial activity of some sulfa drugs through linkage to certain phthalazin-1(2H)-one scaffolds;Hany S.Ibrahim 等;《European Journal of Medicinal Chemistry》;20140807;第85卷;第482页路线3,第484页第4.1.3页 * |
One-Step Synthesis of Isocoumarins and 3-Benzylidenephthalides via Ligandless Pd-Catalyzed Oxidative Coupling of Benzoic Acids and Vinylarenes;Debkumar Nandi 等;《J. Org. Chem.》;20130318;第78卷;第3447页表3,第3448页合成路线4 * |
Pd-free Sonogashira coupling: one pot synthesis of phthalide via domino Sonogashira coupling and 5-exo-dig cyclization;Shubhendu Dhara 等;《RSC Adv.》;20140829;第4卷;第42605-42606页表2 * |
RN:749900-26-3;ACS;《STN Registry数据库》;20170425;第1-11页 * |
Synthesis of 3-substituted isoindolin-1-ones via a tandem desilylation, cross-coupling, hydroamidation sequence under aqueous phase-transfer conditions;Socrates B. Munoz 等;《Org. Biomol. Chem》;20151124;第14卷;第88页表2,第89页表3 * |
丁苯酞防治神经系统性疾病作用机制的研究进展;廖应养 等;《海峡药学》;20171231;第29卷(第4期);第84-87页 * |
Also Published As
Publication number | Publication date |
---|---|
CN108752300A (zh) | 2018-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107698492B (zh) | 一类2-羟基查尔酮胺类化合物及其用途 | |
EP0074863B1 (fr) | Nouveau dérivé de la pyridazine actif sur le système nerveux central | |
CN102846598A (zh) | 香豆素在制备AGEs形成抑制剂中的应用 | |
CN104271581B (zh) | 用作电压门控钠通道调制剂的2-(吡啶-2基)-1,7-二氮杂螺[4.4]壬-6-酮化合物 | |
CN108752300B (zh) | 苄烯叉苯肽类化合物及其药物组合物和其应用 | |
CN111689901A (zh) | 一类具有tdo、ido1双重抑制活性的化合物及制备治疗神经退行性疾病药物的用途 | |
EA037951B1 (ru) | Фенольное соединение и его комбинация с бензодиазепином, конденсированным с 1,4-дигидропиридином, для лечения поражений центральной нервной и сосудистой систем | |
CN101307038A (zh) | 4-苄基哌连乙亚胺酰(亚胺甲基苯)肼类化合物、其制备方法、药物组合物和用途 | |
CN105732595A (zh) | 基于萜类衍生物的par-1抑制剂及其制备方法和在治疗血栓性疾病中的用途 | |
CN106831799A (zh) | 羟基苯乙烯吡啶曼尼希碱类化合物、其制备方法和用途 | |
RU2135162C1 (ru) | Лекарственный препарат для нейропротекции (варианты) | |
CN101092414A (zh) | 一类6-芳基-3-环氨基甲基吡喃酮类衍生物的制备及用途 | |
CN108409738A (zh) | 3,4-亚甲二氧基苯基取代四氢-β-咔啉哌嗪二酮类衍生物及其用途 | |
CN110386881B (zh) | 二芳基乙烯类化合物及其药物组合物和其应用 | |
CN108069942A (zh) | 苯酞吡唑酮类偶联物、其制备方法和用途 | |
CN108570042B (zh) | 一种含1,3,4-噻二唑的吲哚酮衍生物、制备方法及应用 | |
CN108883103A (zh) | 哌啶基痛敏肽受体化合物 | |
CN108026069A (zh) | 2,3,4,5-四氢吡啶-6-胺衍生物 | |
CN106883225B (zh) | 一种具有1,2,4-恶二唑-结构片段的香豆素衍生物及其应用 | |
JP2641915B2 (ja) | N−〔置換アルキリデン〕−1,2,3,4−テトラヒドロ−9−アクリジンアミン | |
CN104860847A (zh) | 利凡斯的明和咖啡酸、阿魏酸的二聚体,其制备方法及其药物组合物 | |
CN1990478B (zh) | 6-芳基-3-取代亚甲基吡喃酮类化合物及其制备方法和用途 | |
CN110272349B (zh) | 一种2’-羟基-3苯基苯丙酮化合物及其制备方法和用途 | |
CN101142214B (zh) | 奥卡哌酮盐及含奥卡哌酮盐的药用组合物 | |
CN1255130A (zh) | 化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
OL01 | Intention to license declared |